Top Markets
Coin of the day
TaiRx, Inc. TaiRx, Inc.

TaiRx, Inc.

6580
Rang in aandelen #25842
TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a... TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for cancer and other diseases. The company's clinical pipeline includes CVM-1118, an oral anti-cancer drug currently undergoing Phase II clinical trials, and Rexis, an add-on injection therapy for sepsis patients, which is in Phase III trials. In its pre-clinical stage, TaiRx is developing TRX-711 for secondary hyperparathyroidism, TRX-920 as an oral delivery formulation, and TRX-105, a molecule designed to treat and alleviate symptoms of various types of colitis. Beyond its developmental drugs, TaiRx also offers Zelnite, a medication that helps maintain patients' blood selenium levels and supports their immune systems. The company's future endeavors also involve the development of nodal diagnostic devices and innovative antibody-based drugs.
Aandeelprijs
$0.40861751
Marktkapitalisatie
$45.81M
Verandering (1 dag)
-1.15%
Verandering (1 jaar)
-46.41%
Land
TW
Handel TaiRx, Inc. (6580)

Categorie

Koersgeschiedenis voor TaiRx, Inc. (6580)
Hoogste slotkoers: $0.42 op 2026-08-01

Laagste slotkoers: $1.41 op 2017-06-01
Koersgeschiedenis van TaiRx, Inc. van 2017 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2026 (TTM) -13.06%
2025 -14.32%
2024 -0.12%
2023 -32.09%
2022 -18.00%
2021 52.04%
2020 57.15%
2019 -14.81%
2018 -18.47%
2017 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$539.14 36.71%
US
$1.04K 56.86%
NL
$120.74 -14.98%
AU
$761.87 7.04%
CH
$130.43 385.07%
US